EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 20 / No 3 (Mars 2004) Med Sci (Paris), 20 3 (2004) 317-324 References
Free Access
Issue
Med Sci (Paris)
Volume 20, Number 3, Mars 2004
Page(s) 317 - 324
Section M/S revues
DOI https://doi.org/10.1051/medsci/2004203317
Published online 15 March 2004
  1. Soussi T, May P. Structural aspects of the p53 protein in relation to gene evolution : second look. J Mol Biol 1996; 260 : 623–37. [Google Scholar]
  2. Courtois S, Verhaegh G, North S, et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002; 44 : 6722–8. [Google Scholar]
  3. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90 : 809–19. [Google Scholar]
  4. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating death-inducing and dominant negative activities. Mol Cell 1998; 2 : 305–16. [Google Scholar]
  5. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants : p63, p73 and the rise of p53. Trends Genet 2002; 18 : 90–5. [Google Scholar]
  6. Nakagawa T, Takahashi M, Ozaki T, et al. Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Mol Cell Biol 2002; 22 : 2575–85. [Google Scholar]
  7. Kartasheva N, Contente A, Lenz-Stöppler C, et al. p53 induces the expression p73 delta N, establishing an autoregulatory feedback loop. Oncogene 2002; 21 : 4715–22. [Google Scholar]
  8. Vossio S, Palescandolo E, Pediconi N, et al. DeltaN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 2002; 21 : 3796–803. [Google Scholar]
  9. Larsen CJ. The ARF-p53 pathway : a line of defense against oncogenic signals. Bull Cancer 1998; 85 : 9–19. [Google Scholar]
  10. Zeng X, Chen L, Jost CA, et al. Mdm2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999; 19 : 3257–66. [Google Scholar]
  11. Minty A, Dumont X, Kaghad M, Caput D. Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1 interacting proteins and a SUMO-1 interaction motif. J Biol Chem 2000; 275 : 36316–23. [Google Scholar]
  12. Calabro V, Gelsomina M, Parisi T, et al. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem 2002; 277 : 2674–81. [Google Scholar]
  13. Stiewe T, Pützer BM. Role of p73 in malignancy tumor suppressor or oncogene ? Cell Death Differ 2002; 9 : 237–45. [Google Scholar]
  14. Jost CA, Marin MC, Kaelin WG. p73 is a human p53-related protein that can induce apoptosis. Nature 1997; 389 : 191–4. [Google Scholar]
  15. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416 : 560–4. [Google Scholar]
  16. Sah VP, Attardi LD, Mulligan GJ, et al. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 1995; 10 : 175–80. [Google Scholar]
  17. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356 : 215–21. [Google Scholar]
  18. Miller FD, Pozniak CD, Walsh GS. Neuronal life and death : an essential role for the p53 family. Cell Death Differ 2000; 7 : 800–88. [Google Scholar]
  19. Lowe S, Ryley H, Jacks T, Houssman D. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74 : 957–67. [Google Scholar]
  20. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398 : 708–13. [Google Scholar]
  21. Celli J, Duijf P, Hamel BC, et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 1999; 99 : 143–53. [Google Scholar]
  22. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurobiological, pheromonal and inflammatory defects but lack spontaneous tumors. Nature 2000; 404 : 99–103. [Google Scholar]
  23. Pozniak CD, Radinovic S, Yang A, et al. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 2000; 289 : 304–6. [Google Scholar]
  24. Meyer G, Perez-Garcia CG, Abraham H, Caput D. Expression of p73 and Reelin in the developing human cortex. J Neurosci 2002; 22 : 4973–86. [Google Scholar]
  25. Allart S, Martin H, Détraves C, et al. Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of ΔN-p73. J Biol Chem 2002; 277 : 29063–8. [Google Scholar]
  26. Moll UT, LaQuaglia M, Bénard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995; 92 : 4407–11. [Google Scholar]
  27. Wolff A, Technau A, Ihling C, et al. Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complex. Oncogene 2001; 20 : 1307–17. [Google Scholar]
  28. Naka M, Ozaki T, Takada N, et al. Functional characterization of naturally occurring mutants (P405R and P425L) or p73alpha and p73beta found in neuroblastoma and lung cancer. Oncogene 2001; 14 : 3568–72. [Google Scholar]
  29. Ahomadegbe JC, Tourpin S, Kaghad M, et al. Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancer : prevalence of alterations in inflammatory breast cancers. Oncogene 2000; 19 : 5413–8. [Google Scholar]
  30. Yan H, Yuan W, Velculescu VE, et al. Allelic variation of human gene expression. Science 2002; 297 : 1143. [Google Scholar]
  31. Fillippovich I, Sorokina N, Gatei M, et al. Transactivation deficient p73alpha (p73 Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 2001; 2 : 514–22. [Google Scholar]
  32. Douc-Rasy S, Barrois M, Echeynne M, et al. DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol 2002; 160 : 631–9. [Google Scholar]
  33. Zaika A, Slade N, Erster S, et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002; 196 : 765–80. [Google Scholar]
  34. Casciano I, Mazzocco K, Boni L, et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002; 9 : 229–30. [Google Scholar]
  35. De Laurenzi V, Raschella G, Barcaroli D, et al. Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J Biol Chem 2000; 27 : 15226–31. [Google Scholar]
  36. Nikolaev AY, Li M, Puskas N, et al. Parc : a cytoplasmic anchor for p53. Cell 2003; 112 : 29–40. [Google Scholar]
  37. Goldschneider D, Blanc E, Raguenez G, et al. Forced p73 expression induces nuclear accumulation of endogenous p53 protein. Cancer Lett 2003; 197 : 99–103. [Google Scholar]
  38. Goldschneider D, Blanc E, Raguenez G, et al. Differential response of p53 target to p73 overexpression in SH-SYSY neuroblastoma cell line. J. Cell Sci 2004; 117 : 293–301. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.